[Kallikrein-protease inhibitors (contrical, gordox) in the complex treatment of myocardial infarction].
One hundred and forty-nine of 199 patients with myocardial infarction (MI) were treated with varying doses of kallikrein-protease inhibitors (KPI), contrical or gordox, for 4 to 5 days as part of combined treatment. KPI added to combined treatment at early dates of MI contributed significantly to the elimination or abatement of some syndromes and complications (pain syndrome, acute circulatory insufficiency, abdominal syndromes, resorption-necrotic syndrome, etc.), improvement of the re-adaptation potential, and early recovery of myocardial metabolism, as evidenced by serial measurements of enzymemia and myoglobinemia, ECG monitoring from 12 leads, and cardiotopography from 35 leads, limiting the necrosis area and the ultimate size of myocardial damage. KPI treatment in the given doses produced no side effects.